Website
News25/Ratings12
News · 26 weeks44+150%
2025-10-262026-04-19
Mix1690d
- Other8(50%)
- SEC Filings3(19%)
- Analyst2(13%)
- Offering2(13%)
- Earnings1(6%)
Latest news
25 items- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-FDaix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it had filed its 2025 Universal Registration Document for the year ended December 31, 2025, including the management report and the annual financial report, with the French Autorité des Marchés Financiers ("AMF") and its 2025 Annual Report on Form 20-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC"). These documents can be accessed
- SECSEC Form 20-F filed by Inventiva S.A.20-F - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva reports 2025 full year results and provides a business updateRevenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)Cash runway expected until the middle of the first quarter of 20273Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approvedTopline results of NATiV3 Phase 3 clinical trial expected for the fourth quarter of 2026The Company will host a conference call on March 31, 2026, at 8 a.m. EDT / 2 p.m. CEST Daix (France), New York City (New York, Uni
- PRInventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial ResultsDaix (France), New York (United States), March 23, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it will release its 2025 full-year financial results on Monday, March 30, 2026, after market close in the United States. Inventiva's management will hold a conference call in English, followed by a Q&A session, on Tuesday, March 31, 2026, at 8:00 am (New York), 2:00 pm (Paris). Participants wishing to join the conference call by phone and ask questions must register in advance here. Upon regis
- ANALYSTTruist initiated coverage on Inventiva with a new price targetTruist initiated coverage of Inventiva with a rating of Buy and set a new price target of $13.00
- PRInventiva to Participate in Four Upcoming March Investor ConferencesDaix (France), New York (United States), February 26, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the Company's leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2, 2026Time of fireside chat: 10:30am ESTLocation: Boston, Massachusetts Leerink Global Healthcare Conference – March 9-11, 2026Date: Tuesday, March 10, 2026Time of presentation: 10
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inventiva S.A.SCHEDULE 13G/A - Inventiva S.A. (0001756594) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inventiva S.A.SCHEDULE 13G/A - Inventiva S.A. (0001756594) (Subject)
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva reports preliminary 2025¹ fiscal year financial resultsCash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its certain preliminary unaudited financial r
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inventiva S.A.SCHEDULE 13G/A - Inventiva S.A. (0001756594) (Subject)
- PRInventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Daix (France), New York (United States), February 4, 2025 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New York Palace in New York City. Inventiva leadership will also hold one-on-one meetings during the conference. The fireside chat details are as follows: Date: Wednesday, February 11, 2026Tim
- ANALYSTBarclays initiated coverage on Inventiva with a new price targetBarclays initiated coverage of Inventiva with a rating of Overweight and set a new price target of $18.00
- PRHalf-Year Review of Inventiva's Liquidity Contract with Kepler CheuvreuxDaix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2025: Cash: € 526,751.56Number of shares: 58,515 Number of executions on buy side on semester: 2,332Number of ex
- ANALYSTLeerink Partners initiated coverage on Inventiva with a new price targetLeerink Partners initiated coverage of Inventiva with a rating of Outperform and set a new price target of $12.00
- ANALYSTUBS resumed coverage on Inventiva with a new price targetUBS resumed coverage of Inventiva with a rating of Buy and set a new price target of $12.00
- PRInventiva to Present at the 44th Annual J.P. Morgan Healthcare ConferenceDaix (France), New York City (New York, United States), December 17, 2025 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that CEO Andrew Obenshain has been invited to present a corporate overview, and will engage with Inventiva's leadership team in investor meetings, at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The conference is being held on January 12-15, 2026 at the Westin St. Francis in San Francisco, California. Inventiva leadership is also scheduling one-on-one meetings Wedne
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRResults of the Votes of the Combined Shareholders' General Meeting of November 27, 2025Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the results of the votes of its Combined Shareholders' Meeting. The Combined Shareholders' Meeting was held on Thursday November 27, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Pierre Broqua. Mr. Pierre Broqua proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of th
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva reports 2025 Third Quarter Financial Information¹Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, including net proceeds from the November 2025 public offering. Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its cash position as of September 30, 2025 and its revenues for t
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Inventiva S.A.SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Inventiva S.A.SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)